Is AbbVie (ABBV) a Buy Right Now?
A plain-English read on AbbVie stock — what the chart and the numbers are saying today, with no jargon and no hype.
What this means, in plain English
AbbVie is currently priced at $250.33, reflecting a modest daily move of 0.35%. The stock is trending upward, as it sits comfortably above its 200-day average of $226.67. This 200-day average acts as a long-term benchmark to help investors see if a stock is generally moving in a positive direction.
With an RSI (Relative Strength Index) of 51.6, the stock is in a neutral zone, meaning it is neither overbought nor oversold. It is currently positioned between its recent floor of $241.2 and its ceiling of $267.47, showing a stable range for those watching the current market behavior.
Should you buy AbbVie stock?
The data supports a buy rating because the price remains above its key long-term averages. While no investment is guaranteed, the current trend suggests stability rather than extreme movement. Always ensure this fits your personal risk tolerance before taking any action.
Is ABBV a good stock for beginners?
AbbVie is a large, established company, which often makes it a common starting point for new investors. However, with a P/E ratio of 70.5—a measure of the price paid for each dollar of earnings—it is important to remember that larger stocks can still fluctuate based on broader market conditions.
What's driving ABBV right now
The stock price of $250.33 is currently above its 200-day average of $226.67.
The stock has found a recent floor of $241.2, providing a level of historical stability.
The P/E ratio of 70.5 indicates that investors are paying a premium for the company's current earnings.
The stock is trading below its 52-week resistance ceiling of $267.47, which may limit immediate upside.
What AbbVie actually does
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
AbbVie by the numbers
Wall Street consensus on ABBV is Buy. That is the analyst community's view, shown for context — it is not our read and not a recommendation.
Who owns AbbVie?
Institutions — pension funds, asset managers, index providers — hold 78.5% of ABBV, and the concentration matters: the largest single holder alone controls 8.46% of the company.
| Holder | Shares | % held |
|---|---|---|
| 149.49M | 8.46% | |
| 115.40M | 6.53% | |
| 82.60M | 4.67% |
Names withheld — plus 3 more records not shown.
See who owns itWhat AbbVie insiders have been doing
Executives and directors must disclose their own trades in company stock. Of the last 6 disclosed transactions we hold for AbbVie, none were an open-market buy or sell — they are awards, vesting, option exercises or derivative conversions, which is normal and says nothing about conviction either way. Insiders sell for many ordinary reasons — scheduled plans, tax, diversification — so a sale is not by itself a signal.
| Insider | Date | Type | Shares | Value |
|---|---|---|---|---|
| 2026-05-08 | AWARD / VEST | 1.1K | — | |
| 2026-05-08 | AWARD / VEST | 1.1K | — | |
| 2026-05-08 | AWARD / VEST | 1.1K | — |
Names withheld — plus 3 more records not shown.
See which insidersThe numbers behind the read
Who in Washington has been trading ABBV?
Members of Congress must disclose trades over $1,000 within 45 days under the STOCK Act. At least 25 disclosures name ABBV — filed by 12 separate members or more and worth $53K–$445K combined (filings report bands, never exact amounts). 16 purchase-side, 9 sale-side, most recently on 2026-05-05.
| Member | Date | Action | Amount filed |
|---|---|---|---|
| 2026-05-05 | SELL | $1,001 - $15,000 | |
| 2026-05-05 | SELL | $1,001 - $15,000 | |
| 2025-12-18 | SELL | $1,001 - $15,000 |
Names withheld — plus 22 more records not shown.
See which membersAbbVie is a buy today because it maintains a positive trend above its long-term averages while holding steady in a neutral RSI range.
Don't guess. Practice this trade first.
Buy it with virtual cash and watch how it plays out — before a dollar of your own is on the line.
Practice ABBV risk-free in your paper portfolioPaper trading, the AI Read & live indicators are inside a Money GPS membership — one price, the whole platform.
Beginner questions about ABBV
Should I buy ABBV stock?+
The data indicates a buy as the price is trending above the 200-day average of $226.67.
Is ABBV a good long-term investment?+
While we cannot predict the future, the stock is currently trading in a stable range between $241.2 and $267.47.
Is ABBV a buy or a sell?+
Based on the current upward trend and the price of $250.33, the data supports a buy rating.
Is ABBV overvalued?+
With a P/E ratio of 70.5, the stock is priced significantly higher relative to its earnings compared to lower-valued alternatives.
Is ABBV a good stock for beginners?+
It is a large company, but beginners should note the P/E ratio of 70.5 and the 52-week range of $190.75 to $267.47 before deciding.
Important disclaimer
This page is for educational and informational purposes only and is not financial, investment, tax, or legal advice, nor a recommendation, offer, or solicitation to buy, sell, or hold AbbVie (ABBV) or any other security. The Money GPS is not a registered investment adviser, broker-dealer, or financial planner, and no content here should be relied upon to make an investment decision.
The verdict, indicators, and commentary are generated automatically — in part using AI — from third-party market data (via Yahoo Finance) that may be delayed, incomplete, or inaccurate, and is provided “as is” without any warranty. Figures reflect the market as of 2026-08-17 and change constantly; the read above may already be out of date. A “Buy,” “Hold,” or “Be Careful” label is a simplified, rules-based signal for beginners — not a price target or a guarantee of any outcome.
All investing involves risk, including the possible loss of your entire principal. Past performance and historical patterns do not guarantee future results. Always do your own research and consult a licensed financial professional who knows your personal circumstances before investing. You are solely responsible for your own investment decisions. The Money GPS and its authors may hold positions in the securities discussed and accept no liability for any loss arising from the use of this information.